Sartan associated enteropathy – case report and review of the literature

Česká verzia

Authors: J. Cyrany ¹; T. Vašátko ¹; M. Nová ²; E. Hovorková ²; J. Macháč ³; J. Szanyi ³; M. Kopáčová ¹
Authors place of work: II. interní gastroenterologická klinika LF UK a FN Hradec Králové ¹; Fingerlandův ústav patologie, LF UK a FN Hradec Králové ²; Klinika infekčních nemocí LF UK a FN Hradec Králové ³
Published in the journal: Gastroent Hepatol 2016; 70(2): 150-156
Category: Clinical and Experimental Gastroenterology: Case Report
doi: https://doi.org/10.14735/amgh2016csgh.info01

Summary

Sartan-associated enteropathy is a sprue-like diarrhoeal disease induced by sartans (especially olmesartan) and is characterised by damage to the small intestine. Villous atrophy with lymphocytic infiltration of lamina propria is usually present and can be associated with intraepithelial lymphocytosis and/or subepithelial collagen deposits. The course of the disease is sometimes severe; however, withdrawal of medication leads to the complete reversal of symptoms and drug re-challenge results in the reappearance of the clinical signs of the disease. This side effect of the drug is relatively rare compared with the number of patients treated with olmesartan. Nevertheless, it represents a frequent and important diagnostic alternative in cohorts of patients with non-coeliac sprue. The disease is presumably caused by an autoimmune mechanism in predisposed individuals. We present a case report of telmisartan-associated enteropathy.

Key words:
olmesartan – sprue – enteropathy – angiotensin II type 1 receptor blockers – celiac disease

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
26. 8. 2015

Accepted:
22. 9. 2015

Zdroje

1. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. [online]. Available from: www.fda.gov/downloads/Drugs/DrugSafety/UCM359496.pdf.

2. Rubio-Tapia A, Herman ML, Ludvigsson JFet al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 2012; 87(8): 732–738. doi: 10.1016/j.mayocp.2012.06.003.

3. Ianiro G, Bibbò S, Montalto M et al. Systematic review: Sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther 2014; 40(1): 16–23. doi: 10.1111/apt.12780.

4. Talbot GH. Small bowel histopathologic findings suggestive of celiac disease in an asymptomatic patient receiving olmesartan. Mayo Clin Proc 2012; 87(12): 1231–1232. doi: 10.1016/j.mayocp.2012.09.011.

5. DeGaetani M, Tennyson CA, Lebwohl B et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol 2013; 108(5): 647–653.

6. Dreifuss SE, Tomizawa Y, Farber NJ et al. Spruelike enteropathy associated with olmesartan: an unusual case of severe diarrhea. Case Rep Gastrointest Med 2013; 2013: 618071. doi: 10.1155/2013/618071.

7. Nielsen JA, Steephen A, Lewin M. Angiotensin-II inhibitor (olmesartan)-induced collagenous sprue with resolution following discontinuation of drug. World J Gastroenterol 2013; 19(40): 6928–6930. doi: 10.3748/wjg.v19.i40.6928.

8. Nunge D, Eoche M, Fumery M et al. Severe enteropathy with villous atrophy olmesartan medoxomil-associated. Therapie 2013; 68(6): 419–421. doi: 10.2515/therapie/2013057.

9. Stanich PP, Yearsley M, Meyer MM. Olmesartan-associated sprue-like enteropathy. J Clin Gastroenterol 2013; 47(10): 894–895. doi: 10.1097/MCG.0b013e31829a27e6.

10. Tran TH, Li H. Olmesartan and drug-induced enteropathy. P T 2014; 39(1): 47–50.

11. Theophile H, David XR, Miremont-Salame G et al. Five cases of sprue-like enteropathy in patients treated by olmesartan. Dig Liver Dis 2014; 46(5): 465–459. doi: 10.1016/j.dld.2013.12.014.

12. Gaur V, Albeldawi M, Weber L. Chronic diarrhea and weight loss. Gastroenterology 2014; 146(2): 347,591. doi: 10.1053/j.gastro.2013.10.002.

13. de Fonseka A, Tuskey A, Moskaluk C. A case of olmesartan induced enteropathy. Inflamm Bowel Dis 2012; 18: S17.

14. Marthey L, Cadiot G, Seksik P et al. Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther 2014; 40(9): 1103–1109. doi: 10.1111/apt.12937.

15. Bhat N, Anupama NK, Yelsangikar A et al. Olmesartan-related sprue-like enteropathy. Indian J Gastroenterol 2014; 33(6): 564–567. doi: 10.1007/s12664-014-0506-7.

16. Fiorucci G, Puxeddu E, Colella R et al. Se-vere spruelike enteropathy due to olmesartan. Rev Esp Enferm Dig 2014; 106(2): 142–144.

17. Gallivan C, Brown I. Olmesartan induced enterocolitis. Pathology 2014; 46(4): 360–361. doi: 10.1097/PAT.0000000000000104.

18. Heerasing N, Hair C, Wallace S. Olmesartan-induced enteropathy. Intern Med J 2015; 45(1): 117–118. doi: 10.1111/imj.12635.

19. Halevy D, Teeuwen U, Kohlhof P. A new spruelike disease as a cause of severe diarrhea. Dtsch Med Wochenschr 2014; 139(45): 2290–2293. doi: 10.1055/s-0034-1387342.

20. Ould Sidi Mohamed M, Colardelle P. Enteropathy due to olmesartan. Ann Cardiol Angeiol (Paris) 2015. doi: 10.1016/j.ancard.2015.04.022.

21. van Beurden YH, Nijeboer P, Janssen J et al. Diarrhoea and malabsorption due to olmesartan use. Ned Tijdschr Geneeskd 2014; 158.

22. Cyrany J, Vasatko T, Machac J et al. Letter: telmisartan-associated enteropathy – is there any class effect? Aliment Pharmacol Ther 2014; 40(5): 569–570. doi: 10.1111/apt.12850.

23. Cammarota G, Ianiro G, Bibbo S et al. Letter: telmisartan associated enteropathy – is there any class effect? Authors’ reply. Aliment Pharmacol Ther 2014; 40(5): 570. doi: 10.1111/apt.12870.

24. Herman ML, Rubio-Tapia A, Wu TT et al. A case of severe sprue-like enteropathy associated with valsartan. ACG Case Rep J 2015; 2(2): 92–94. doi: 10.14309/crj.2015.15.

25. Scialom S, Malamut G, Meresse B et al. Gastrointestinal disorder associated with olmesartan mimics autoimmune enteropathy. PLoS One 2015; 10(6). e0125024. doi: 10.1371/journal.pone.0125024.

26. de Araújo AA, Borba PB, de Souza FH et al. In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity. Biol Pharm Bull 2015; 38(5): 746–752. doi: 10.1248/bpb.b14-00847.

27. Khan AS, Peter S, Wilcox CM. Olmesartan-induced enteropathy resembling celiac disease. Endoscopy 2014; 46 (Suppl 1): 97–98. doi: 10.1055/s-0033-1359132.

28. Fukushima M, Kitamoto H, Inokuma T et al. Severe spruelike enteropathy associated with olmesartan observed by double--balloon enteroscopy. Gastrointest Endosc 2016; 83(1): 269–270. doi: 10.1016/j.gie.2015.06.004.

29. Lagana SM, Braunstein ED, Arguelles--Grande C et al. Sprue-like histology in patients with abdominal pain taking olmesartan compared with other angiotensin receptor blockers. J Clin Pathol 2015; 68(1): 29–32. doi: 10.1136/jclinpath-2014-202615.

30. Rubio-Tapia A. Editorial: sprue-like enteropathy associated with Olmesartan – broadening the differential diagnosis of enteropathy. Aliment Pharmacol Ther 2014; 40(11–12): 1362–1363. doi: 10.1111/apt.13000.

31. Marietta EV, Cartee A, Rishi A et al. Drug-induced enteropathy. Dig Dis 2015; 33(2): 215–220. doi: 10.1159/000370205.

32. Hartranft ME, Regal RE. „Triple Phase“ budesonide capsules for the treatment of olmesartan-induced enteropathy. Ann Pharmacother 2014; 48(9): 1234–1237.

33. Abdelghany M, Gonzalez L 3rd, Slater J et al. Olmesartan associated sprue-like enteropathy and colon perforation. Case Rep Gastrointest Med 2014; 2014: 494098. doi: 10.1155/2014/494098.

34. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239–245.

35. Menne J, Haller H. Olmesartan and intestinal adverse effects in the ROADMAP study. Mayo Clin Proc 2012; 87(12): 1230–1231. doi: 10.1016/j.mayocp.2012.10.005.

36. Sanford ML, Nagel AK. A review of current evidence of Olmesartan medoxomil mimicking symptoms of celiac dis-ease. J Pharm Pract 2014. In Press. doi:10.1177/0897190014527320.

37. Padwal R, Lin M, Etminan M et al. Comparative effectiveness of olmesartan and other angiotensin receptor blockers in diabetes mellitus: retrospective cohort study. Hypertension 2014; 63(5): 977–983. doi: 10.1161/HYPERTENSIONAHA.113.02855.

38. Greywoode R, Braunstein ED, Arguelles-Grande C et al. Olmesartan, other antihypertensives, and chronic diarrhea among patients undergoing endoscopic procedures: a case-control study. Mayo Clin Proc 2014; 89(9): 1239–1243. doi: 10.1016/j.mayocp.2014.05.012.

39. Basson M, Mezzarobba M, Weill A et al. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. Gut 2015. doi: 10.1136/gutjnl-2015-309690.

40. Souhrn údajů o přípravku Sarten 10 mg. Sp.zn.sukls165021/2014. [online]. Dostupné z: www.sukl.cz/modules/medication/download.php?file=SPC71413.pdf&type=spc&as=sarten-10-spc.

41. Lebwohl B, Ludvigsson JF. Editorial: sprue-like enteropathy due to olmesartan and other angiotensin receptor blockers – the plot thickens. Aliment Pharmacol Ther 2014; 40(10): 1245–1246. doi: 10.1111/apt.12960.